1-12 of 12
Melanie M Frigault
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

Beatrix Stelte-Ludwig, Tibor Schomber, Raquel Izumi, Harvey Wong, Melanie M Frigault, Anne-Sophie Rebstock, Sebastian Ludwig, Arushi Mithal, Amy J Johnson, Ahmed Hamdy
Journal: Blood
Blood (2023) 142 (Supplement 1): 1435.
https://doi.org/10.1182/blood-2023-182260
Published: 2023
Journal Articles

Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

Ritul Sharma, Melanie M Frigault, Amy J Johnson, Raquel Izumi, Ahmed Hamdy, Joseph Birkett, Beatrix Stelte-Ludwig, Luke Maese, Norman J. Lacayo, Aru Narendran
Journal: Blood
Blood (2023) 142 (Supplement 1): 4293.
https://doi.org/10.1182/blood-2023-180567
Published: 2023
Journal Articles

VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models

Beatrix Stelte-Ludwig, George Clemens, Tibor Schomber, Melanie M. Frigault, Amy J. Johnson, Hans-Georg Lerchen, Raquel Izumi, Ahmed Hamdy
Journal: Blood
Blood (2022) 140 (Supplement 1): 5955–5956.
https://doi.org/10.1182/blood-2022-167556
Published: 2022
Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Mazyar Shadman, Anthony R. Mato, Connie Lee Batlevi, Ian W. Flinn, Martin Gutierrez, Marc Uemura, Don A. Stevens, Daniel Morillo, John C. Byrd, Melanie M. Frigault, George Clemens, Xin Huang, Raquel Izumi, Harvey Wong, Renee Breed, Hermes Garban, Amy J. Johnson, Beatrix Stelte-Ludwig, Arushi Mithal, Joseph Birkett, Ahmed Hamdy, Kerry A. Rogers
Journal: Blood
Blood (2022) 140 (Supplement 1): 9454–9456.
https://doi.org/10.1182/blood-2022-167651
Published: 2022
Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran
Journal: Blood
Blood (2022) 140 (Supplement 1): 10685–10686.
https://doi.org/10.1182/blood-2022-169917
Published: 2022
Journal Articles

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher, Larry Beaver, Katie Williams, Shelley Orwick, Brandi R. Walker, Charles Thomas Gregory, Matthew Purcell, Alexander Pan, Pearlly S. Yan, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Stuart Hwang, James S. Blachly, John C. Byrd, Rosa Lapalombella
Journal: Blood
Blood (2021) 138 (Supplement 1): 270.
https://doi.org/10.1182/blood-2021-153812
Published: 2021
Journal Articles

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Melanie M. Frigault, Harvey Wong, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1192.
https://doi.org/10.1182/blood-2021-150917
Published: 2021
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey
Journal: Blood
Blood (2019) 134 (Supplement_1): 2571.
https://doi.org/10.1182/blood-2019-128872
Published: 2019
Journal Articles

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD, Andre Goy, MD, Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD PhD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Franck Morschhauser, MD, Carlos Panizo, MD PhD, Bijal D. Shah, MD, Andrew Davies, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven LE Gouill, MD PhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Richa Dua, PharmD, Melanie M. Frigault, PhD, Raquel Izumi, PhD, Dorothy Nguyen, MD PhD, Priti Patel, MD, Ming Yin, PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2876.
https://doi.org/10.1182/blood-2018-99-110327
Published: 2018